Cargando…

Complex Mutations & Subpopulations of Deletions at Exon 19 of EGFR in NSCLC Revealed by Next Generation Sequencing: Potential Clinical Implications

Microdeletions at exon 19 are the most frequent genetic alterations affecting the Epidermal Growth Factor Receptor (EGFR) gene in non-small cell lung cancer (NSCLC) and they are strongly associated with response to treatment with tyrosine kinase inhibitors. A series of 116 NSCLC DNA samples investig...

Descripción completa

Detalles Bibliográficos
Autores principales:	Marchetti, Antonio, Del Grammastro, Maela, Filice, Giampaolo, Felicioni, Lara, Rossi, Giulio, Graziano, Paolo, Sartori, Giuliana, Leone, Alvaro, Malatesta, Sara, Iacono, Michele, Guetti, Luigi, Viola, Patrizia, Mucilli, Felice, Cuccurullo, Franco, Buttitta, Fiamma
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3407088/ https://www.ncbi.nlm.nih.gov/pubmed/22848739 http://dx.doi.org/10.1371/journal.pone.0042164

Ejemplares similares

Assessment of EGFR Mutations in Circulating Tumor Cell Preparations from NSCLC Patients by Next Generation Sequencing: Toward a Real-Time Liquid Biopsy for Treatment
por: Marchetti, Antonio, et al.
Publicado: (2014)

An innovative diagnostic strategy for the detection of rare molecular targets to select cancer patients for tumor-agnostic treatments
por: Marchetti, Antonio, et al.
Publicado: (2019)

Adjuvant osimertinib treatment in patients with early stage NSCLC (IB-IIIA): pathological pathway adaptations
por: Marchetti, Antonio, et al.
Publicado: (2022)

Pulmonary resection for NSCLC in octogenarians: a single center experience
por: Di Russo, S, et al.
Publicado: (2011)

Mutational Profile of GNAQ (Q209) in Human Tumors
por: Lamba, Simona, et al.
Publicado: (2009)

Early prediction of resistance to tyrosine kinase inhibitors by plasma monitoring of EGFR mutations in NSCLC: a new algorithm for patient selection and personalized treatment
por: Buttitta, Fiamma, et al.
Publicado: (2020)

A fatal case of post endobronchial ultrasound transbronchial needle aspiration endobronchial haemorrhage: a case report and review of the literature
por: Mucilli, Felice, et al.
Publicado: (2021)

BRCA gene amplification in primary peritoneal high-grade serous carcinoma patient with intrinsic resistance to platinum treatment: a case report
por: Buttitta, Fiamma, et al.
Publicado: (2023)

Optimizing Single Agent Panitumumab Therapy in Pre-Treated Advanced Colorectal Cancer()()
por: Gasparini, Giampietro, et al.
Publicado: (2014)

POLE exonuclease domain mutations in endometrial carcinoma: a case report
por: Pasciuto, Maria Paola, et al.
Publicado: (2023)

Spotlight on Mobocertinib (TAK-788) in NSCLC with EGFR Exon 20 Insertion Mutations
por: Zhang, Shannon S, et al.
Publicado: (2021)

NTRK gene fusions in solid tumors: agnostic relevance, prevalence and diagnostic strategies
por: Marchetti, Antonio, et al.
Publicado: (2022)

Full cost of diagnostic pathology for lung carcinoma in Italy: results from four Pathology Units
por: Lazzaro, Carlo, et al.
Publicado: (2023)

Weekly alternate intensive regimen FIrB/FOx in metastatic colorectal cancer patients: an update from clinical practice
por: Cortellini, Alessio, et al.
Publicado: (2019)

SARS-CoV-2 peritoneal positivity and emergency surgery: is there any putative predisposing factor?
por: Barone, Mirko, et al.
Publicado: (2021)

Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for Management
por: Veillon, Remi, et al.
Publicado: (2022)

Long-term survivors with immunotherapy in advanced NSCLC: is ‘cure’ within reach?
por: Monteverdi, Sara, et al.
Publicado: (2020)

Activity and bioavailability of tepotinib for leptomeningeal metastasis of NSCLC with MET exon 14 skipping mutation
por: Tanaka, Hisashi, et al.
Publicado: (2021)

Clinical and pathological characteristics of 11 NSCLC patients with c-MET exon 14 skipping
por: Chen, Hualin, et al.
Publicado: (2022)

Real-World Response and Outcomes in Patients With NSCLC With EGFR Exon 20 Insertion Mutations
por: Ou, Sai-Hong Ignatius, et al.
Publicado: (2023)

Digital Pathology and PD-L1 Testing in Non Small Cell Lung Cancer: A Workshop Record
por: Pagni, Fabio, et al.
Publicado: (2020)

First-line nivolumab + ipilimumab in advanced NSCLC: CheckMate 227 subpopulation analyses in Asian patients
por: O’Byrne, K.J., et al.
Publicado: (2022)

Clinical impact of the lung tissue transcriptome in a teenager with multifocal invasive mucinous adenocarcinoma—a case report
por: Di Carlo, Emma, et al.
Publicado: (2020)

Erratum to clinical impact of the lung tissue transcriptome in a teenager with multifocal invasive mucinous adenocarcinoma—a case report
por: Di Carlo, Emma, et al.
Publicado: (2020)

Response to Afatinib in a Patient with NSCLC Harboring Novel EGFR Exon 20 Insertion Mutations
por: Lin, Ling, et al.
Publicado: (2020)

Case Report: Durable therapy response to Osimertinib in rare EGFR Exon 18 mutated NSCLC
por: Cekay, Michael, et al.
Publicado: (2023)

Efficacy of Second-Line Pemetrexed-Carboplatin in EGFR-Activating Mutation-Positive NSCLC: Does Exon 19 Deletion Differ from Exon 21 Mutation?
por: Joshi, Amit, et al.
Publicado: (2017)

Molecular characteristics and clinical outcomes of EGFR exon 19 indel subtypes to EGFR TKIs in NSCLC patients
por: Su, Jian, et al.
Publicado: (2017)

Acquired Exon 14 MET Mutation Associated With Resistance to Alectinib in a Patient With ALK–Rearranged NSCLC
por: Daniel, Catherine, et al.
Publicado: (2020)

Leptomeningeal Response to Capmatinib After Progression on Crizotinib in a Patient With MET Exon 14–Mutant NSCLC
por: Cravero, Paola, et al.
Publicado: (2020)

Reduction in parvalbumin expression not loss of the parvalbumin-expressing GABA interneuron subpopulation in genetic parvalbumin and shank mouse models of autism
por: Filice, Federica, et al.
Publicado: (2016)

Extraordinary and prolonged erlotinib-induced clinical response in a patient with EGFR wild-type squamous lung cancer in third-line therapy: a case report
por: Gambale, Elisabetta, et al.
Publicado: (2017)

Tumor Initiation Capacity and Therapy Resistance Are Differential Features of EMT-Related Subpopulations in the NSCLC Cell Line A549()
por: Tièche, Colin Charles, et al.
Publicado: (2018)

Case Report: Afatinib Treatment in a Patient With NSCLC Harboring a Rare EGFR Exon 20 Mutation
por: Zöchbauer-Müller, Sabine, et al.
Publicado: (2021)

Devil in the detail: MET overexpression fails as surrogate marker for MET exon 14 splice site mutations in NSCLC
por: Strickland, Matthew R., et al.
Publicado: (2020)

Continuation of Tyrosine Kinase Inhibitor is Associated with Survival Benefit in NSCLC Patients with Exon 19 Deletion after Solitary Progression
por: Na, Feifei, et al.
Publicado: (2017)

TRLS-03. Intracranial activity of tepotinib in patients with MET exon 14 (METex14) skipping NSCLC enrolled in VISION
por: Bestvina, Christine M, et al.
Publicado: (2021)

Characterization of MET Exon 14 Skipping Alterations (in NSCLC) and Identification of Potential Therapeutic Targets Using Whole Transcriptome Sequencing
por: Kim, So Yeon, et al.
Publicado: (2022)

SYST-06 INTRACRANIAL ACTIVITY OF TEPOTINIB IN PATIENTS WITH MET EXON 14 (METEX14) SKIPPING NSCLC ENROLLED IN VISION
por: Leighl, Natasha, et al.
Publicado: (2022)

Detection and characterization of classical and “uncommon” exon 19 Epidermal Growth Factor Receptor mutations in lung cancer by pyrosequencing
por: Righi, Luisella, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_e07o2oipafdttkbl1uelocpeg3